DPP-4 Inhibition With Sitagliptin and the Risk for Hypoglycaemia in the Fasting State in Subjects With Type 2 Diabetes Treated to Fasting Plasma Glucose Targets With Insulin Glargine and Metformin
Phase of Trial: Phase II
Latest Information Update: 27 Mar 2018
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 05 Jan 2018 Planned End Date changed from 30 Jun 2019 to 30 Jul 2019.
- 05 Jan 2018 Planned primary completion date changed from 30 Jun 2019 to 30 Jul 2019.